RESUMEN
The pharmacological properties of the novel neurokinin-1 (NK(1)) receptor antagonist FK886, ([3,5-bis(trifluoromethyl)phenyl][(2R)-2-(3-hydroxy-4-methylbenzyl)-4-{2-[(2S)-2-(methoxymethyl)morpholin-4-yl]ethyl}piperazin-1-yl]methanone dihydrochloride), were studied. FK886 potently inhibited the binding of [(125)I]Bolton-Hunter-labeled substance P ([(125)I]BH-SP; 100 pM) to human NK(1) receptors expressed in Chinese hamster ovary (CHO) cells (IC(50)=0.70 nM). It also possessed high affinities for dog, ferret, gerbil and guinea pig NK(1) receptors, but not for rat NK(1) receptor. FK886 was highly selective for the NK(1) receptor, with 250- and >20000-fold selectivity for human NK(1) over NK(2) and NK(3), respectively. Further, it did not inhibit radioligand binding at 54 different sites, including receptors, ion channels and transporters. FK886 inhibited substance P (3.2 nM)-induced inositol phosphate formation in human NK(1) receptor-expressing CHO cells (IC(50)=1.4 nM) without stimulating NK(1) receptors. The antagonism exerted by FK886 against human NK(1) receptor was insurmountable in saturation binding experiments, with both the affinity and B(max) of [(125)I]BH-SP being significantly reduced. After intravenous administration, FK886 (0.01-0.1 mg/kg) dose-dependently inhibited the foot-tapping behavior induced by intracerebroventricular administration of a selective NK(1) receptor agonist, GR73632 (10 pmol), in gerbils, with significant inhibition being observed at doses of 0.032-0.1 mg/kg, indicating excellent brain penetration. The brain penetration of FK886 was further demonstrated by the cerebral distribution of radioactivity after intravenous injection of radiolabeled FK886. Taken together, these results demonstrate that FK886 is a potent, highly selective and centrally active, insurmountable antagonist of the NK(1) receptor, and suggest that FK886 antagonizes various NK(1) receptor-mediated biological effects in the central nervous system.
Asunto(s)
Morfolinas/farmacología , Antagonistas del Receptor de Neuroquinina-1 , Piperazinas/farmacología , Animales , Células CHO , Cricetinae , Cricetulus , Gerbillinae , Humanos , Masculino , Fragmentos de Péptidos/farmacología , Ratas , Ratas Sprague-Dawley , Receptores de Neuroquinina-1/metabolismo , Proteínas Recombinantes/antagonistas & inhibidores , Proteínas Recombinantes/metabolismo , Sustancia P/análogos & derivados , Sustancia P/farmacología , Distribución TisularRESUMEN
The antiemetic properties of a novel neurokinin-1 (NK1) receptor antagonist, FK886 ([3,5-bis(trifluoromethyl)phenyl][(2R)-2-(3-hydroxy-4-methylbenzyl)-4-{2-[(2S)-2-(methoxymethyl)morpholin-4-yl]ethyl}piperazin-1-yl]methanone dihydrochloride), were studied in dog models of cisplatin- and apomorphine-induced emesis. Intravenously administered FK886 (0.32-1 mg/kg) significantly inhibited cisplatin-induced acute emesis during the 5-h observation period. Nearly complete inhibition was observed at 1 mg/kg. At an equivalent dose range, orally administered FK886 also significantly inhibited emesis, indicating good oral absorption. Similarly, FK886 inhibited apomorphine-induced emetic responses effectively following both intravenous and oral administration. The effects were long lasting, with 1.6 mg/kg of FK886 completely blocking apomorphine-induced retching and vomiting after a 12-h pretreatment period. Furthermore, FK886 showed rapid onset of antiemetic activity after oral administration. At doses of 0.32 mg/kg or more, a pretreatment time of 0.5 h was sufficient for complete inhibition of apomorphine-induced emetic responses. This fast onset after oral administration was supported by pharmacokinetic data, which demonstrated plasma levels of FK886 after oral administration reached levels similar to those 30 min after intravenous administration. These results suggest that FK886 has excellent antiemetic properties in dogs, and that its rapid-onset and long-lasting properties might make it a promising antiemetic agent.
Asunto(s)
Antieméticos/uso terapéutico , Morfolinas/uso terapéutico , Antagonistas del Receptor de Neuroquinina-1/uso terapéutico , Piperazinas/uso terapéutico , Vómitos/tratamiento farmacológico , Animales , Antieméticos/sangre , Antieméticos/farmacocinética , Apomorfina , Cisplatino , Perros , Femenino , Masculino , Morfolinas/sangre , Morfolinas/farmacocinética , Antagonistas del Receptor de Neuroquinina-1/sangre , Antagonistas del Receptor de Neuroquinina-1/farmacocinética , Piperazinas/sangre , Piperazinas/farmacocinética , Vómitos/inducido químicamente , Vómitos/metabolismoRESUMEN
BACKGROUND: At present, there are few available animal models of progressive renal failure originating from mesangial proliferative glomerulonephritis (GN). In the current study, we examined the usefulness of anti-Thy-1 monoclonal antibody (mAb) 1-22-3-induced GN in uninephrectomized rats as a model of progressive renal failure by analysing the similarities to human disease. METHODS: GN was induced by intravenous injection of mAb 1-22-3 into uninephrectomized male Wistar rats. The natural course of the disease was analysed in this model for 47 weeks. The effect of treatment with the angiotensin-converting enzyme inhibitor, captopril, on renal functional outcome was also examined in this model for 23 weeks, beginning from 1 week after antibody injection. RESULTS: Injection of mAb 1-22-3 induced a persistent proteinuria during the entire study period. Animals showed a progressive decline in renal function and 63% died by week 47. Severe glomerular and tubulointerstitial lesions were consistently observed. Treatment with captopril significantly inhibited increases in proteinuria and blood pressure, and attenuated renal injury. Captopril also retarded the progression of renal failure, and decreased mortality. Finally, the level of proteinuria was significantly correlated with the rate of decline in renal function, and the reduction in proteinuria by captopril was accompanied by a slower progression of renal failure. CONCLUSIONS: The mAb 1-22-3-induced GN in a uninephrectomized rat model simulates the clinical manifestations of human disease, indicating that this model may be useful for studying progressive renal failure and for investigating new therapeutic strategies against renal failure.
Asunto(s)
Anticuerpos Monoclonales/toxicidad , Glomerulonefritis/inducido químicamente , Isoanticuerpos/toxicidad , Fallo Renal Crónico/etiología , Nefrectomía , Animales , Presión Sanguínea/fisiología , Nitrógeno de la Urea Sanguínea , Creatinina/sangre , Creatinina/orina , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Estudios de Seguimiento , Mesangio Glomerular/ultraestructura , Glomerulonefritis/complicaciones , Glomerulonefritis/metabolismo , Fallo Renal Crónico/metabolismo , Fallo Renal Crónico/patología , Túbulos Renales/ultraestructura , Masculino , Fotomicrografía , Proteinuria/complicaciones , Proteinuria/metabolismo , Proteinuria/fisiopatología , RatasRESUMEN
The complement system is indispensable for host defence. Unregulated activation, however, is related to various diseases. In order to elucidate the significance of complement, methodology that disrupts the complement system is essential. Advances in molecular genetics made direct modulations of the genes of complement components and their regulatory proteins feasible. One method is disruption of genes that encode complement components. Several studies have been conducted with these mice in models such as nephrotoxic serum (NTS) nephritis, ischaemia reperfusion and immune complex-mediated glomerulonephritis. These studies all showed that depletion of complement components ameliorated the severity of the diseases. Complement regulatory protein serves a regulatory role in the complement system. Genetically engineered animals that overexpress these proteins have been employed to elucidate their biological roles. Mice overexpressing soluble complement regulatory proteins were protected from the lesion of both NTS and the glomerular endothelial injury model. In contrast, knockout mice that lack expression of decay-accelerating factor (DAF), a complement regulatory protein, developed severe glomerular lesions when subnephritogenic doses of NTS were administered. These genetically engineered animals shed light on the mechanism of initiation and progression of kidney disease.